Quince Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Quince Therapeutics, Inc. (QNCX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-56.83-31.39-51.66-89.95-76.85-36.98
Depreciation & Amortization0.190.320.200.340.330.19
Deferred Income Tax0.000.00-0.280.000.000.00
Stock Based Compensation4.755.2216.6229.8514.470.00
Change in Working Capital-0.481.98-9.83-4.2610.231.90
Change in Accounts Payable0.93-0.29-5.941.360.480.00
Change in Other Working Capital5.691.67-0.310.209.750.00
Other Operating Activities5.691.67-0.310.200.372.42
Net Cash from Operating Activities-31.90-18.29-44.04-62.93-50.82-33.28
Investing Activities
Capital Expenditures-0.26-0.160.13-0.18-0.050.06
Acquisitions0.00-2.1210.590.000.000.00
Purchases of Investments-89.56-113.78-75.02-38.79-52.380.00
Sales/Maturities of Investments111.73111.217.4797.92-52.38-17.69
Other Investing Activities2.35-1.000.000.000.000.00
Net Cash from Investing Activities21.91-5.7618.0058.95-52.43-17.75
Financing Activities
Debt Repayment0.00-0.01-0.050.00-0.03-0.56
Common Stock Issued0.230.150.616.81118.9177.83
Other Financing Activities-5.000.000.000.000.000.00
Net Cash from Financing Activities-4.780.140.716.81118.8877.37
Summary
Effect of Forex Changes on Cash0.230.080.180.060.000.00
Net Change in Cash-14.77-23.91-25.332.8315.6326.34
Cash at Beginning of Period20.7544.5869.7266.8451.2124.87
Cash at End of Period6.2120.7544.5869.7266.8451.21
Free Cash Flow-32.16-18.45-44.10-63.11-50.87-33.33